Epstein-Barr Virus and Gastric Cancer

  • Ming-Shiang Wu
  • Chia-Tung Shun
  • Jaw-Town Lin


Chronic inflammation, triggered by infectious agents, has a key role in the development of malignancies (Aggarwal et al. 2006). The estimated total of infection-attributable cancer in the year 2002 is 1.9 million cases, or 17.8‥ of the global cancer burden (Parkin 2006). Among the principal agents, Helicobacter pylori and Epstein-Barr virus (EBV) are two common and widely disseminated pathogens throughout the world, and account for 5.5‥ and 1‥ of total malignancies, respectively (Parkin 2006).

H. pylori has been classified by the International Agency for Research on Cancer (IARC) as a class I carcinogen, i.e., a clear and unquestionable causative agent for gastric cancer (GC). EBV was isolated in 1964 from Burkitt's lymphoma (Epstein et al. 1964), which was first described in 1958 to be unique endemic jaw tumors in equatorial African (Burkitt 1958). Shortly after that, Old and colleagues discovered the link between EBV and epithelial malignancies. They incidentally...


Gastric Cancer Pylorus Infection Intestinal Metaplasia Atrophic Gastritis Human Leukocyte Antigen Class 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, and Sethi G. 2006. Inflammation and cancer: how hot is the link? Biochem Pharmacol 72:1605–21.CrossRefPubMedGoogle Scholar
  2. Au WY, Pang A, Chan EC, Chu KM, Shek TWH, and Kwong YL. 2005. Epstein-Barr virus-related gastric adenocarcinoma: an early secondary cancer post hemopoietic stem cell transplantation. Gastroenterology 129:2058–63.CrossRefPubMedGoogle Scholar
  3. Baer R, Bankier AT, Biggin MD, et al. 1984. DNA sequence and expression of the B95—8 Epstein-Barr virus genome. Nature 310:207–11.CrossRefPubMedGoogle Scholar
  4. Barua RR, Uozaki H, Chong JM, Ushiku T, Hino R, Chang MS, Nagai H, and Fukayama M. 2006. Phenotype analysis by MUC2, MUC5AC, MUC6, and CD10 expression in Epstein-Barr virus-associated gastric carcinoma. J Gastroenterol 41:733–9.CrossRefPubMedGoogle Scholar
  5. Burgess DE, Woodman CB, Flavell KJ, Rowlands DC, Crocker J, Scott K, Biddulph JP, Young LS, and Murrray PG. 2002. Low prevalence of Epstein-Barr virus in incident gastric adeno-carcinomas from United Kingdom. Br J Cancer 86:702–4.CrossRefPubMedGoogle Scholar
  6. Burke AP, Yen TS, Shekitka KM, and Sobin LH. 1990. Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction. Mod Pathol 3:377–80.PubMedGoogle Scholar
  7. Burkitt D. 1958. A sarcoma involving the jaws in African children. Br J Surg 46:218–24.CrossRefPubMedGoogle Scholar
  8. Chan WY, Chan AB, Liu AY, Chow JH, Ng EK, and Chung SS. 2001. Chromosome 11 copy number gains and Epstein-Barr virus-associated malignancies. Diagn Mol Pathol 10:223–7.CrossRefPubMedGoogle Scholar
  9. Chang MS, Kim WH, Kim CW, and Kim YJ. 2000. Epstein-Barr virus in gastric carcinoma with lymphoid stroma. Histopathology 37:309–15.CrossRefPubMedGoogle Scholar
  10. Chang MS, Lee HS, Kim HS, Kim SH, Choi SI, Lee BL, Kim CW, Kim YI, Yang M, and Kim WH. 2003. Epstein-Barr virus and microsatellite instability in gastric carcinogenesis. J Pathol 199:447–52.CrossRefPubMedGoogle Scholar
  11. Chang MS, Uozaki M, Chong JM, Ushiku T, Sakuma K, Ishikawa S, Hino R, Barua RR, Iwasaki Y, Arai K, Fukii H, Nagai H, and Fukayama M. 2006. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res 12:2995–3002.CrossRefPubMedGoogle Scholar
  12. Chapel J, Fabiani B, Davi F, Raphel M, Tepper M, Champault G, and Guettier C. 2000. Epstein-Barr virus and gastric carcinoma in Western patients: comparison of pathological parameters and p53 expression in EBV-positive and negative tumors. Histopathology 36:252–61.CrossRefPubMedGoogle Scholar
  13. Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen CJ, and Yang CS. 2001. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 345:1877–82.CrossRefPubMedGoogle Scholar
  14. Cho YJ, Chang MS, Park SH, Kim HS, and Kim WH. 2001. In situ hybridization of Epstein-Barr virus in tumor cells and tumor-infiltrating lymphocytes of the gastrointestinal tract. Hum Pathol 32:297–301.CrossRefPubMedGoogle Scholar
  15. Chong JM, Sakuma K, Sudo M, Osawa T, Ohara E, Uozaki H, Shibahara J, Kuroiwa K, Tominaga S, Hippo Y, Aburatani H, Funata N, and Fukayama M. 2002. Interleukin-1beta expression in human gastric carcinoma with Epstein-Barr virus infection. J Virol 76:6825–31.CrossRefPubMedGoogle Scholar
  16. Chu PG, Chang KL, Chen WG, Chen YY, Shibata D, Hayashi K, Bacchi C, Bacchi M, and Weiss M. 1999. Epstein-Barr virus (EBV) nuclear antigen (ENBA)-4 mutations in EBV-associated malignancies in three different populations. Am J Pathol 155:941–7.PubMedGoogle Scholar
  17. Corvalan A, Ding S, Koriyama C, Carrasquilla G, Backhouse C, Urzua L, Argandona J, Palma M, Eizuru Y, and Akiba S. 2006. Association of a distinctive strain of Epstein-Barr virus with gastric cancer. Int J Cancer 118:1736–42.CrossRefPubMedGoogle Scholar
  18. Dutta N, Gupta A, Mazumder DN, and Banerjee S. 2006. Down-regulation of locus-specific human lymphocyte antigen class I expression in Epstein-Barr virus-associated gastric cancer: implication for viral-induced immune evasion. Cancer 106:1685–93.CrossRefPubMedGoogle Scholar
  19. Epstein MA, Achong BC, and Barr YM. 1964. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet i:702–3.Google Scholar
  20. Etoh T, Kanai Y, Ushijima S, Nakagawa T, Nakanashi Y, Sasako M, Kitano S, and Hirohashi S. 2004. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poor tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancer. Am J Pathol 154:689–99.Google Scholar
  21. Evans AS. 1972. Clinical syndromes associated with EB virus infection. Ann Intern Med 18:77–93.Google Scholar
  22. Feng WH, Israel B, Raab-Traub N, Busson P, and Kenney SC. 2002a. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res 62:1920–6.Google Scholar
  23. Feng WH, Westphal E, Mauser A, Raab-Traub N, Gulley ML, Busson P, and Kenney SC. 2002b. Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZRF1 or BRLF1 to treat EBV-positive tumors. J Virol 76:10951–9.CrossRefGoogle Scholar
  24. Galetsky SA, Tsvetnov VV, Land CE, Afanasieva TA, Petrovichev NN, Gurtsevitch VE, and Tokunaga M. 1997. Epstein-Barr virus-associated gastric cancer in Russia. Int J Cancer 73:786–9.CrossRefPubMedGoogle Scholar
  25. Gorzer I, Puchhammer-Stockl E, van Esser JWJ, Niester HGM, and Cornelissen JJ. 2007. Associations among Epstein-Barr virus subtypes, human leukocyte antigen class I alleles and the development of posttransplantation lymphoproliferative disorder in bone marrow transplant recipients. Clin Infect Dis 44:693–5.CrossRefPubMedGoogle Scholar
  26. Hao Z, Koriyama C, Akiba S, Li J, Luo X, Itoh T, Eizuru Y, and Zou J. 2002. The Epstein-Barr virus-associated gastric carcinoma in Southern and Northern China. Oncol Rep 9:1293–8.PubMedGoogle Scholar
  27. Harn HJ, Chang JY, Wang MW, Ho LI, Lee HS, Chiang JH, and Lee WH. 1995. Epstein-Barr virus-associated gastric adenocarcinomas in Taiwan. Hum Pathol 26:267–71.CrossRefPubMedGoogle Scholar
  28. Hayashi K, Chen WG, Chen YY, Murakami I, Chen HL, Ohara N, Nose S, Hamaya K, Matsui S, Bacchi MM, Bacchi CE, Chang KL, and Weiss LM. 1998. Deletion of Epstein-Barr virus latent membrane protein 1 gene in Japanese and Brazilian gastric carcinomas, metastatic lesions, and reactive lymphocytes. Am J Pathol 152:191–8.PubMedGoogle Scholar
  29. Hermann K, and Niedobitek G. 2003. Epstein-Barr virus–associated carcinomas: facts and fiction. J Pathol 199:140–5.CrossRefGoogle Scholar
  30. Herrera-Goepfert R, Reyes E, Hernadez-Avila M, Mohar A, Shinkura R, Fujiyama C, Akiba S, Eiruru Y, Harada Y, and Tokunaga M. 1999. Epstein-Barr virus-associated gastric carcinoma in Mexico: analysis of 135 consecutive gastrectomies in two hospitals. Mod Pathol 12:873–8.PubMedGoogle Scholar
  31. Hoshikawa Y, Satoh Y, Murakami M, Maeta M, Kaibara N, Ito M, Kurata T, and Sairenji T. 2002. Evidence of the lytic infection of Epstein-Barr virus (EBV) in EBV-positive gastric carcinoma. J Med Virol 66:351–9.CrossRefPubMedGoogle Scholar
  32. Hsieh LL, Lin PJ, Chen TC, and Ou JT. 1998. Frequency of Epstein-Barr virus-associated gastric adenocarcinoma in Taiwan. Cancer Lett 129:125–9.CrossRefPubMedGoogle Scholar
  33. IARC monographs on the evaluation of carcinogenic risks to humans. Infections with Epstein-Barr virus and human herpes viruses. Vol.70. Lyon: IARC; 1997.Google Scholar
  34. Iwarkiri D, Eizuru Y, Tokunaga M, and Takada K. 2003. Autocrine growth of Epstein-Barr virus-positive gastric carcinoma cells mediated by an Epstein-Barr virus-encoded small RNA. Cancer Res 63:7062–7.Google Scholar
  35. Iwasaki Y, Chong JM, Hayashi Y, Ikeno R, Arai K, Kitamura M, Koike M, Hirai K, and Fukayama M. 1998. Establishment and characterization of a human Epstein-Barr virus-associated gastric carcinoma in SCID mice. J Virol 72:8321–6.PubMedGoogle Scholar
  36. Jung EJ, Lee YM, Lee BL, Chang MS, and Kim HW. 2007. Ganciclovir augments the lytic induction and apoptosis induced by chemotherapeutic agents in an Epstein-Barr virus-infected gastric carcinoma cell line. Anticancer Drugs 18:79–85.Google Scholar
  37. Kaizaki Y, Hosokawa O, Sakurai S, and Fukayama M. 2005. Epstein-Barr virus-associated gastric carcinoma in the remnant stomach: de novo and metachronous gastric remnant carcinoma. J Gastroenterol 40:570–7.CrossRefPubMedGoogle Scholar
  38. Kang GH, Lee S, Kim WH, Lee HW, Kim JC, Rhyu MG, and Ro J Y. 2002. Epstein-Barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and contributes CpG island methylator phenotype-positive gastric carcinoma. Am J Pathol 160:787–94.PubMedGoogle Scholar
  39. Kattoor J, Koriyama C, Akiba S, Itoh T, Ding S, Eizuru Y, Abraham EK, and Chandralekha B. 2002. Epstein-Barr virus-associated gastric carcinoma in southern India: a comparison with a large-scale Japanese series. J Med Virol 68:384–9.CrossRefPubMedGoogle Scholar
  40. Kijima Y, Hokita S, Takao S, Baba M, Natsugoe S, Yoshinaka H, Aridome K, Otsuji T, Itoh T, Tokunaga M, Eizuru Y, and Aikou T. 2001. Epstein-Barr virus involvement is mainly restricted to lymphoepithelial type of gastric carcinoma among various epithelial neoplasms. J Med Virol 64:513–8.CrossRefPubMedGoogle Scholar
  41. Kim DN, Chae HS, Oh ST, Kang JH, Park CH, Park WS, Takada K, Lee JM, Lee WK, and Lee SK. 2007. Expression of viral microRNAs in Epstein-Barr virus-associated gastric carcinoma. J Virol 81:1033–6.CrossRefGoogle Scholar
  42. Kim MA, Lee HS, Yang HK, and Kim WH. 2004. Cytokeratin expression profile in gastric carcinoma. Hum Pathol 35:576–81.CrossRefPubMedGoogle Scholar
  43. Klein E, Kis LL, and Klein G. 2007. Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interaction. Oncogene 26:1297–305.CrossRefPubMedGoogle Scholar
  44. Koriyama C, Akiba S, Iriya K, Yamaguti T, Hamada GS, Itoh T, Eizuru Y, Aikou T, Watanabe S, Tsugane S, and Tokunaga M. 2001a. Epstein-Barr virus-associated gastric carcinoma in Japanese Brazilians and non-Japanese Brazilians in San Paulo. Jpn J Cancer Res 92:911–7.Google Scholar
  45. Koriyama C, Shinkura R, Hamasaki Y, Fujiyoshi T, Eizuru Y, and Tokunaga M. 2001b. Human leukocyte antigen related to Epstein-Barr virus-associated gastric carcinoma in Japanese patients. Eur J Cancer Prev 10:69–75.CrossRefGoogle Scholar
  46. Koriyama C, Akiba S, Itoh T, Kijima Y, Sueyoshi K, Corvaian A, Herrer-Goepfer R, and Eieuru Y. 2002. Prognostic significance of Epstein-Barr virus involvement in gastric carcinoma in Japan. Int J Mol Med 10:635–9.PubMedGoogle Scholar
  47. Koriyama C, Akiba S, Minakami Y, and Eizuru Y. 2005. Environmental factors related to Epstein-Barr virus-associated gastric cancer in Japan. J Exp Clin Cancer Res 24:547–53.PubMedGoogle Scholar
  48. Kume T, Oshima K, Yamasshita Y, Shirakusa T, and Kikuchi M. 1999. Relationship between Fas-ligand expression on carcinoma cell and cytotoxic T-lymphocyte response in lymphoepi-thelioma-like cancer of the stomach. Int J Cancer 84:339–43.CrossRefPubMedGoogle Scholar
  49. Kusano M, Toyota M, Suzuki H, Akino K, Aoki F, Fujita M, Hosokawa M, Shinomura Y, Imai K, and Tokino T. 2006. Genetic, epigenetic, and clinicopathologic features of gastric carcinoma with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer 106:1467–79.CrossRefPubMedGoogle Scholar
  50. Kuzushima K, Nakamura S, Nakamura T, Yamamura Y, Yokoyama N, Fujita M, Kiyono T, and Tsurumi T. 1999. Increased frequency of antigen-specific CD8(+) cytotoxic T lymphocytes infiltrating an Epstein-Barr virus-associated gastric carcinoma. J Clin Invest 104:163–71.CrossRefPubMedGoogle Scholar
  51. Lee HS, Chang MS, Yang HK, Lee BL, and Woo HK. 2004. Epstein-Barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with Epstein-Barr virus-negative carcinoma. Clin Cancer Res 10:1698–705.CrossRefPubMedGoogle Scholar
  52. Leonicini L, Vindigni C, Megha T, Funto I, Pacenti I, Musaro M, Renieri A, Seri M, Anagnostopoulos J, and Tosi P. 1993. Epstein-Barr virus and gastric cancer: data and unanswered questions. Int J Cancer 53:898–901.CrossRefGoogle Scholar
  53. Levine PH, Stemmermann G, Lennette ET, Hidesheim A, Shibata D, Nomura H, Okita K, Miura O, Shimizu N, and Takada K. 1995. Elevated antibody titers to Epstein-Barr virus prior to the diagnosis of Epstein-Barr virus-associated gastric adenocarcinoma. Int J Cancer 60:642–4.CrossRefPubMedGoogle Scholar
  54. Lo YM. 2001a. Quantitative analysis of Epstein-Barr virus DNA in plasma and serum: applications in tumor detection and monitoring. Ann NY Acad Sci 945:68–72.CrossRefGoogle Scholar
  55. Lo YM, Chan W Y, Ng EK, Chan LY, Lai PB, Tam JS, and Chung SC. 2001b. Circulating Epstein-Barr virus DNA in the serum of patients with gastric carcinoma. Clin Cancer Res 7:1856–9.Google Scholar
  56. Luo B, Murakami M, Fukuda M, Fujioka A, Yanagihara K, and Sairenji T. 2004. Characterization of Epstein-Barr virus infection in a human signet ring cell gastric carcinoma cell line, HSC-39. Microbes Infect 6:429–39.CrossRefPubMedGoogle Scholar
  57. Luo B, Wang Y, Wang XF, Liang H, Yan LP, Huang BH, and Zhao P. 2005. Expression of Epstein-Barr virus genes in EBV-associated gastric carcinomas. World J Gastroenterol 11:629–33.PubMedGoogle Scholar
  58. Minarovits J. 2006. Epigenotypes of latent herpesvirus genomes. Curr Top Microbiol Immunol 310:61–80.CrossRefPubMedGoogle Scholar
  59. Niedobitek G, and Herbst M. 2006. In situ detection of Epstein-Barr virus and phenotype determination of EBV-infected cells. Methods Mol Biol 326:115–37.PubMedGoogle Scholar
  60. Nilsson K, Klein G, Henle, W, and Henle G. 1971. The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV. Int J Cancer 81:443–50.Google Scholar
  61. Nishikawa J, Yanai H, Hirano A, Okamoto T, Nakamura H, Matsusaki K, Kawano T, Miura O, and Okita K. 2002. High prevalence of Epstein-Barr virus in gastric remnant carcinomas after Billroth-II reconstruction. Scand J Gastroenterol 37:825–9.PubMedGoogle Scholar
  62. Oh ST, Seo JS, Moon UY, Kang KH, Shin DJ, Yoon SK, Kim WH, Park JG, and Lee SK. 2004. A naturally derived gastric cancer cell line shows latency I Epstein-Barr virus infection closely resembling EBV-associated gastric cancer. Virology 320:330–6.CrossRefPubMedGoogle Scholar
  63. Ohfuji S, Osaki M, Tsujitani S, Ikeguchi M, Sairenji T, and Ito H. 1996. Low frequency of apoptosis in Epstein-Barr virus-associated gastric carcinoma with lymphoid stroma. Int J Cancer 68:710–5.CrossRefPubMedGoogle Scholar
  64. Ojima H, Fukuda T, Nakajima T, Takenoshita S, and Nagamachi Y. 1996. Discrepancy between clinical and pathological lymph node evaluation in Epstein-Barr virus-associated gastric cancers. Anticancer Res 16:3081–4.PubMedGoogle Scholar
  65. Okugawa K, Itoh T, Kawashima I, Takesako K, Mazda O, Nukaya I, Yano Y, Yamamoto Y, Yamagishi H, and Ueda Y. 2004. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocyte induced in vitro with autologous lymphoblastoid cell line and LMP2-derived HLA-A24-restricted 9-mer peptide. Oncol Rep 12:725–31.PubMedGoogle Scholar
  66. Old LJ, Boyse EA, Oettgen HF, Harven ED, Geering, Williamson B, and Clifford P. 1966. Precipitating antibody in human serum to an antigen present in cultured Burkitt's lymphoma cells. Proc Natl Acad Sci USA 56:1699–704.CrossRefPubMedGoogle Scholar
  67. Osato T, and Imai S. 1996. Epstein-Barr virus and gastric carcinoma. Semin Cancer Biol 7:175–82.CrossRefPubMedGoogle Scholar
  68. Ott G, Kirchiner T, and Muller-Hermelink HK. 1994. Monoclonal Epstein-Barr virus genomes but lack of EBV related protein expression in different types of gastric carcinoma. Histopathology 25:323–9.CrossRefPubMedGoogle Scholar
  69. Ouburg S, Bart A, Crusius J, Klinkenberg-Knol EC, Mulder CJ, Salvador Pena A, and Morre SA. 2005. A candidate gene approach of immune mediators effecting the susceptibility to and severity of upper gastrointestinal diseases in relation to Helicobacter and Epstein-Barr virus infection. Eur J Gatroenterol Hepatol 17:1213–24.CrossRefGoogle Scholar
  70. Parkin DM. 2006. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118:3030–44.CrossRefPubMedGoogle Scholar
  71. Qiu K, Tomita Y, Hashimoto M, Ohsawa M, Kawano K, Wu DM, and Aozasa K. 1997. Epstein-Barr virus in gastric carcinoma in Suzhou, China and Osaka, Japan: association with clinico-pathologic factors and HLA-subtypes. Int J Cancer 71:155–8.CrossRefPubMedGoogle Scholar
  72. Rugge M, and Genta R. 1999. Epstein-Barr virus: a possible accomplice in gastric oncogenesis. J Clin Gastroenterol 29:3–5.CrossRefPubMedGoogle Scholar
  73. Sakuma K, Chong JM, Sudo M, Ushiku T, Inoue Y, Shibahara J, Uozaki M, Nagai H, and Fukayama M. 2004. High-density methylation of p14ARF and p16INK4A in Epstein-Barr virus-associated gastric carcinoma. Int J Cancer 112:273–8.CrossRefPubMedGoogle Scholar
  74. Sakuma K, Uozaki H, Chong Jm, Hironaka M, Sudo M, Ushiku T, Nagai H, and Fukayama M. 2005. Cancer risk to the gastric corpus in Japanese, its correlation with interleukin-1beta gene polymorphism (+3953*T) and Epstein-Barr virus infection. Int J Cancer 115:93–7.CrossRefPubMedGoogle Scholar
  75. Shibata D, and Weiss LM. 1992. Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol 140:769–74.PubMedGoogle Scholar
  76. Shinkura R, Yamamoto N, Koriyama C, Shinmura Y, Eizuru Y, and Tokunaga M. 2000. Epstein-Barr virus-specific antibodies in Epstein-Barr virus-positive and -negative gastric carcinoma cases in Japan. J Med Virol 60:411–6.CrossRefPubMedGoogle Scholar
  77. Shinohara K, Miyazaki K, Noda N, Satoh D, Terada M, and Wakasugi H. 1998. Gastric diseases related to Helicobacter pylori and Epstein-Barr virus infection. Microbiol Immunol 42:415–21.PubMedGoogle Scholar
  78. Sudo M, Chong JM, Sakuma K, Ushiku T, Uozaki H, Nagai H, Funata N, Matsumoto Y, and Fukayama M. 2004. Promoter hypermethylation of E-cadherin and its abnormal expression in Epstein-Barr virus-associated gastric carcinoma. Int J Cancer 109:194–9.CrossRefPubMedGoogle Scholar
  79. Tajima M, Komuro M, and Okinaga K. 1998. Establishment of Epstein-Barr virus-positive human gastric epithelial lines. Jpn J Cancer Res 89:262–8.PubMedGoogle Scholar
  80. Takada K. 2000. Epstein-Barr virus and gastric carcinoma. J Clin Pathol Mol Pathol 53:255–61.CrossRefGoogle Scholar
  81. Tokunaga M, Uemura Y, Tokudome T, et al. 1993. Epstein-Barr virus-related gastric cancer in Japan: a molecular patho-epidemiological study. Acta Pathol Jpn 43:574–81.PubMedGoogle Scholar
  82. Tokunaga M, and Land CE. 1998. Epstein-Barr virus involvement in gastric cancer: biomarker for lymph node metastasis. Cancer Epidemiol Biomarkers Prev 7:449–50.PubMedGoogle Scholar
  83. van Beek J, zur Hausen A, Klein KE, van de Velde CJ, Middeldorp JM, van den Brule AJ, Meijer CJ, and Bloemena E. 2004. EBV-positive gastric adenocarcinomas: a distinct clinicopatho-logic entity with a low frequency of lymph node involvement. J Clin Oncol 22:664–70.CrossRefPubMedGoogle Scholar
  84. van Rees BP, Caspers E, zur Hausen A, van den Brule A, Drilenburg P, Weterman MA, and Offerhaus GJ. 2002. Different pattern of allelic loss in Epstein-Barr virus-positive gastric cancer with emphasis on the p53 tumor suppressor pathway. Am J Pathol 161:1207–13.PubMedGoogle Scholar
  85. von Rahden BH, Langner C, Brucher BL, Stein HJ, and Sarbia M. 2006. No association of primary adenocarcinomas of the small bowel with Epstein-Barr virus infection. Mol Carcinog 45:349–52.CrossRefGoogle Scholar
  86. Wang Q, Tsao SW, Ooka T, Nicholls Jm, Cheung HW, Fu S, Wong YC, and Wang X. 2006. Anti-apoptotic role of BARF1 in gastric cancer cells. Cancer Lett 238:90–103.CrossRefPubMedGoogle Scholar
  87. Watanabe H, Enjoji M, and Imai T. 1976. Gastric carcinoma with lymphoid stroma: its morphologic characteristics and prognostic correlation. Cancer 38:232–43.CrossRefPubMedGoogle Scholar
  88. Westphal EM, Blackstock W, Feng W, Israel B, and Kenney SC. 2000. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res 60:5781–8.PubMedGoogle Scholar
  89. Wu MS, Shun CT, Wu CC, Hsu TY, Lin MT, Chang MC, Wang HP, and Lin JT. 2000. Epstein-Barr virus-associated gastric carcinomas: relation to H. pylori infection and genetic alterations. Gastroenterology 118:1031–8.CrossRefPubMedGoogle Scholar
  90. Wu MS, Huang SP, Chang YT, Shun CT, Chang MC, Lin MT, Wang HP, and Lin JT. 2002. Tumor necrosis factor-a and interleukin-10 promoter polymorphisms in Epstein-Barr virus-associated gastric carcinoma. J Infect Dis 185:106–9.CrossRefPubMedGoogle Scholar
  91. Yanai H, Murakami T, Yoshiyama H, Takeuchi H, Nishikawa J, Nakamura H, Okita K, Miura O, Shimizu N, and Takada K. 1999. Epstein-Barr virus-associated gastric carcinoma and atrophic gastritis. J Clin Gastroenterol 29:39–43.CrossRefPubMedGoogle Scholar
  92. Yanai H, Nishikawa J, Mizugaki Y, Shimizu, N, Takada K, Matsusaki K, Toda T, Matsumoto Y, Tada M, and Okita K. 1997a. Endoscopic and pathologic features of Epstein-Barr virus-associated gastric carcinoma. Gastrointest Endosc 45:236–42.CrossRefGoogle Scholar
  93. Yanai H, Takada K, Shimizu N, Mizugaki Y, Tada M, and Okita K. 1997b. Epstein-Barr virus infection in non-carcinomatous epithelium. J Pathol 183:293–8.CrossRefGoogle Scholar
  94. Yoshiwara E, Koriyama C, Akiba S, Itoh T, Minakami Y, Chirinos JL, Watanabe J, Takano J, Miyagui J, Hidalgo H, Chacon P, Linares V, and Eizuru Y. 2005. Epstein-Barr virus-associated gastric carcinoma in Lima, Peru. J Exp Clin Cancer Res 24:49–54.PubMedGoogle Scholar
  95. Young LS, and Rickinson AB. 2004. Epstein-Barr virus:40 years on. Nature Rev Cancer 4:757–68.CrossRefGoogle Scholar
  96. Yuen ST, Chung LP, Leung S Y, Luk IS, Chan SY, and Ho J. 1994. In situ hybridization of Epstein-Barr virus in gastric and colorectal adenocarcinomas. Am J Surg Pathol 18:1158–63.CrossRefPubMedGoogle Scholar
  97. zur Hausen A, Brink AA, Craanen ME, Middeldorp JM, Meijer CJ, and van den Brule AJ. 2000. Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarci-nomas: expression of the transforming BARF1 gene. Cancer Res 60:2745–8.PubMedGoogle Scholar
  98. zur Hausen A, Crusus JBA, Murillo LS, Alizadeh BZ, Morre SA, Meijer CJLM, van dan Brule AJC, and Pena AS. 2003. IL-1B promoter polymorphism and Epstein-Barr virus in Dutch patients with gastric carcinoma. Int J Cancer 107:866–7.CrossRefPubMedGoogle Scholar
  99. zur Hausen A, van Grieken NC, Meijer GA, Hermsen MA, Bloemena E, Meuwissen SG, Baak JP, Meijer CJ, Kuipers EJ, and van den Brule AJ. 2001. Distinct chromosomal abnormalities in Epstein-Barr virus-carrying gastric carcinomas tested by comparative genomic hybridization. Gastroenterology121:612–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2009

Authors and Affiliations

  • Ming-Shiang Wu
    • 1
  • Chia-Tung Shun
    • 1
  • Jaw-Town Lin
    • 1
  1. 1.Departments of Internal Medicine and PathologyNational Taiwan University HospitalTaipei

Personalised recommendations